European shares fall again with cenbank meetings in focus



(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* STOXX 600 down for fifth straight session

* Spotlight on Fed, ECB, BoE meetings

* Vifor Pharma, Ocado nudge STOXX 600 higher

* Germany's Ifo slashes GDP growth forecast for 2022 (Updates to close)

By Anisha Sircar and Susan Mathew

Dec 14 (Reuters) - European shares reversed early gains to end lower for a fifth straight session on Tuesday as technology stocks weighed, while the healthcare sector dipped despite a 12.6% surge in Vifor Pharma.

The pan-European STOXX 600 index .STOXX fell 0.8%, hitting session lows after data showed U.S. producer prices came in hotter-than-expected, which saw Wall Street indexes open lower a day ahead of the Federal Reserve's monetary policy decision.

The Fed is expected to signal a faster pullback of asset purchases, while the European Central Bank and the Bank of England will meet on Thursday to determine the course for their monetary policies into 2022.

The International Monetary Fund urged the Bank of England on Tuesday to avoid an "inaction bias" when it comes to raising interest rates as it forecast higher inflation.

"Equity markets will stay skittish as there is tension between Omicron... and a busy calendar for central banks..., while we stand between two earnings seasons," said Nick Nelson, head of European equity strategy at UBS.

"But we're no longer talking about the same restrictions we had in Q1 2021 or 2020, so in the near term, restrictions across Europe will only be a modest drag on growth."

Germany's Ifo institute slashed the country's GDP growth forecast for 2022, saying a fourth COVID-19 wave and persisting supply bottlenecks are slowing down Europe's largest economy.

At least one person died in Britain after contracting the Omicron variant, the first publicly confirmed death globally from the rapidly spreading strain. But Britain is set to remove all 11 countries from its COVID-19 travel red list from Wednesday.

Tech stocks .SX8P lost 2.1%, tracking U.S peers, while the healthcare index .SXDP slipped 1.2%.

Vifor VIFN.S extended gains from Monday after agreeing to be bought by Australian biopharma giant CSL CSX.AX for $11.7 billion.

Also capping losses were miners .SXPP which tracked copper and iron ore prices higher, while rising bond yields and tighter monetary policy appearing on the horizon lifted banks .SX7P .

UniCredit CRDI.MI firmed 4.6% after HSBC raised the Italian lender's target price, while ArcelorMittal MT.AS advanced 8.1% after the world's largest steelmaker announced plans to repurchase some of its debt.

Rentokil RTO.L plunged 12.3% on its $6.7 billion plan to buy U.S. rival Terminix TMX.N , while AutoStore Holdings AUTO.OL dropped 13.4% after it lost a patent infringement lawsuit filed against British online supermarket group Ocado Group OCDO.L .

BT BT.L slid 4.3% after Franco-Israeli entrepreneur Patrick Drahi increased his stake to 18%, prompting a warning from Britain that it would intervene if necessary to protect the telecoms group building the country's critical fibre network.
Reporting by Anisha Sircar in Bengaluru; Editing by Rashmi Aich, Vinay Dwivedi and Alex Richardson

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.